ArticleThrombosis journal2026
Association of novel inflammation markers derived from high-sensitivity C-reactive protein with anemia: a cross-sectional study based on NHANES 2015-2018.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the associations of the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio (HCHR) and the high-sensitivity C-reactive protein to lymphocyte ratio (HCLR) with anemia in the general population.
methodsA cross-sectional analysis was conducted using data from 8638 adults enrolled in the National Health and Nutrition Examination Survey (NHANES) 2015–2018. Anemia was defined according to the World Health Organization (WHO) criteria. HCHR and HCLR were calculated based on laboratory measurements. Multivariable logistic regression models were applied to estimate the associations between HCHR, HCLR, and anemia. Subgroup analyses and smooth curve fitting were performed to assess effect modification and potential nonlinear relationships. Sensitivity analyses were also performed to assess the robustness of the results.
resultsAmong the 8638 participants, 930 individuals had anemia. Compared with non-anemic participants, those with anemia had significantly higher median levels of HCHR (p < 0.001) and HCLR (p < 0.001). In fully adjusted models, higher HCHR (OR = 1.007, 95% CI: 1.002–1.011, p = 0.012) and HCLR (OR = 1.027, 95% CI: 1.013–1.042, p = 0.004) were independently associated with an increased risk of anemia. Compared with the lowest quartile, participants in the highest quartile of both HCHR and HCLR had significantly greater odds of anemia (P for trend < 0.05). Subgroup analyses confirmed the consistency of the associations between HCHR, HCLR, and anemia. Smooth curve fitting revealed nonlinear relationships between HCHR, HCLR, and anemia risk.
conclusionHigher HCHR and HCLR were significantly associated with an increased risk of anemia among U.S. adults, underscoring the potential utility of inflammation-based composite biomarkers in anemia risk stratification. Nevertheless, further prospective studies are warranted to confirm causality and evaluate clinical applicability. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.